Skip to main content
OpenTrials
Recruiting

NCT Number: NCT00345553

Biliary Atresia Study in Infants and Children

Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following aims: To identify the gene or genes implicated in the etiology of BA; To characterize the natural history of the older, non-transplanted child with BA.

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 month–20 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital for Sick Children, Toronto, Ontario, Canada

Loading trial locations.

About this study

Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. A variety of genetic, autoimmune and environmental influences have been hypothesized to be important. Most studies to date have focused on the neonate and young child with BA, yet the older surviving child with BA can provide important information about genetics, as well as, natural history.

The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following hypotheses:

Hypothesis 1: A genetic defect is a likely causative factor for BA among children with BA and multiple congenital anomalies.

Hypothesis 2a: Sentinel events such as variceal bleeding, ascites and growth failure are earlier predictors of death or need for liver transplantation than the pediatric end-stage liver disease score (PELD).

Hypothesis 2b: Health related quality of life will be impaired compared to healthy age matched children and relate to severity of illness.

Hypothesis 2c: Growth failure as measured by anthropometrics and nutritional supplementation will be predictive of onset of sentinel events (ascites, variceal bleed, death, and transplant) in the following 24 months.

This study will be performed by the Childhood Liver Disease Research Network (ChiLDReN), a National Institute of Diabetes & Digestive and Kidney Diseases (NIDDK) funded network.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants need to have a confirmed diagnosis of BA determined by chart review including review of pertinent diagnostic biopsy reports, radiologic reports and surgical reports (if surgery was performed).
  • Participants need to be >6 months of age up to and equal to the age of 20 (participants enrolled at 20 years of age will have one visit).
  • Participants with their native liver.
  • Parent, guardian or participant (if 18 years of age or older) is willing to provide informed consent and, when appropriate, the participant is willing to assent.

Exclusion criteria

  • Currently participating in the ChiLDReN study PROBE.
  • Inability to confirm original diagnostic evaluation of biliary atresia.
  • Inability or unwillingness of family or participant to participate in all scheduled visits.
  • History of liver transplantation.

Treatment and study plan

Primary outcomes

  1. To identify the gene or genes implicated in the etiology of BA

    Time frame: Specimens for this aim are collected once during study, usually at baseline.

    The genetics of BA may be investigated on two levels. The first is to identify a group of patients whose etiology is a result of a genetic defect and the second is to examine the influence of genetics on disease acquisition.

Secondary outcomes

  1. Define the natural history of the older, non-transplanted child with biliary atresia

    Time frame: Observational information collected at entrance into study as well as at each yearly follow-up visit.

    Understanding the natural history of a disease is a prerequisite to interpreting disease severity, identifying patterns of illness, identifying early predictors of outcome and understanding the advantages or trade-offs of therapeutic interventions.

Study contacts

Contact information is provided by the study sponsor or research team.

Melissa Sexton, BBA

CONTACT

[email protected]

734-693-3811

Melissa Sexton, BBA, CCRP

CONTACT

[email protected]

734-693-3811

Sponsors and collaborators

Lead sponsor

Arbor Research Collaborative for Health

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

Biliary Atresia Study in Infants and Children (BASIC)

Acronym: BASIC

Important dates

Study start
2006
Primary completion
2029
Study completion
2029
First posted
Jun 28, 2006
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.